

## **Region V Fall Symposium**

## PROGRAM INFORMATION

Dates: October 5-6, 2017

Location: Holiday Inn Sioux Falls – City Centre

100 West 8<sup>th</sup> Street Sioux Falls, SD 57104

Phone: (605)339-2000

Website: https://www.ihg.com/holidayinn/hotels/us/en/sioux-falls/fsddt/hoteldetail

Contacts for Meeting or Registration Questions

Stacie Lansink <u>stacie.lansink@sdstate.edu</u> Charlotte Romain <u>marsh397@gmail.com</u>

Janice Conway-Klaassen jconwayk@umn.edu

For additional information and meeting contacts for questions, visit the ASCLS Region V Fall Symposium website: www.regionvascls.online

|                                | Thursday, October 5, 2017  |  |  |  |
|--------------------------------|--|--|--|--|
| 11:00-12:30 PM                 | Registration   |  |  |  |
| 12:30-1:30 PM<br>Session # K-1 | Keynote: Sanford Imagenetics: A Story of Genomics and Personalized Medicine  |  |  |  |
|                                | Speaker: Robert E Pyatt, PhD Director, Sanford Medical Genetics Laboratory, Sanford Imagenetics  |  |  |  |
|                                | Sanford Imagenetics is a comprehensive new program that integrates genetics with intern medicine, creating a first-of-its-kind model for high quality and innovative primary care for adult By gauging genomic indications of a health concern, applying preventative regimens, avoidir triggering events and providing targeted treatments, the practice of genomic medicine w revolutionize health care. |  |  |  |
|                                | Level of Instruction: Basic (1.0 Contact Hour)  Objectives: (Upon completion of the session, the participant will be able to)  • Define pharmacogenomics and describe one area of patient care where pharmacogenomics is used  |  |  |  |
|                                | <ul> <li>Recognized the clinical utility of whole exome sequencing in identifying the causes of<br/>congenital genetic disorders</li> </ul>  |  |  |  |
|                                | <ul> <li>Distinguish the education needs for patients and medical providers around human genetics<br/>topics</li> </ul>  |  |  |  |

| 1:45–2:45 PM                | E  | mployee Engagement and Surveys – Can You Feel the Burn  |  |  |  |  |
|-----------------------------|--|---|--|--|--|--|
| Session #1                  | Speaker:   | Dean Porter MLS(ASCP) <sup>CM</sup> Laboratory Director, Ridgeview Medical Center and Clinics   |  |  |  |  |
|                             | A discussion of the different ways of gathering feedback from employees to improve the workplace and how to interpret. How to reach out to groups of different sizes and configuration for making improvements to the workplace and help prevent burnout.  |   |  |  |  |  |
|                             |  | <ul> <li>struction: Intermediate(1.0 Contact Hour)</li> <li>(Upon completion of the session, the participant will be able to)</li> <li>Describe at least 2 different methods for gathering data from staff</li> <li>Discuss interpretation of the data and how to bring this back to the staff</li> <li>Provide examples of building focus groups to build employee participation</li> </ul>  |  |  |  |  |
| 1:45–2:45 PM                | La   | boratory Tools in the Diagnosis and Management of Acute Leukemia: Past, Present and Future  |  |  |  |  |
| Session #2                  | Speaker:   | Sam Milanovich, MD Pediatric Hematologist/Oncologist, Sanford Children's Hospital   |  |  |  |  |
|                             | Leukemia has long been recognized as a disease caused by acquired genetic mutation in developing blood cells. Clinical and basic science research has begun to highlight the genetic diversity of this disease. Early research in some types of leukemia has led to the development of targeted therapies. Current laboratory tools aid in the characterization of disease and provide assessment of response. Emerging technologies will further refine how we diagnose and manage leukemia as we move further into the era of personalized medicine. |   |  |  |  |  |
|                             | Level of Instruction: Intermediate (1.0 Contact Hour) Objectives: (Upon completion of the session, the participant will be able to)  Discuss genetic diversity of acute leukemia  Describe how current lab techniques are important to appropriate treatment profor acute leukemia  Describe how emerging technologies will improve diagnosis and management acute leukemia  |   |  |  |  |  |
| 2:45-3:15 PM                | Break - Hotel Foyer & Room Check In  |   |  |  |  |  |
| 3:15–4:15 PM<br>Session # 3 | Speaker:   | Moving the Cheese – Why Do I Have to Change?  Rochelle Odenbrett, MT(ASCP), MBA Sr. Executive Director, Sanford Health  |  |  |  |  |
|                             | are<br>tern<br>mea   | ether you work in a small Critical Access Hospital lab or a large regional hospital lab, we all being asked to make drastic changes in how we perform laboratory tests. We hearns such as centralizing, standardizing and utilization management, but what does that an to me, and why do I have to change? We will explore this topic together and try to lerstand how we all fit into the bigger picture of the changing health care environment. |  |  |  |  |
|                             |  | <ul> <li>struction: Basic (1.0 Contact Hour)</li> <li>(Upon completion of the session, the participant will be able to)</li> <li>Describe why laboratory tests are being centralized within a health care system</li> <li>Discuss the benefits of standardizing the laboratory testing and equipment within a health care system</li> <li>Identify ways that laboratory staff can play a role in utilization management.</li> </ul>                 |  |  |  |  |

| 3:15-4:15 PM                | The Evolving Role of the Reticulated Platelet  |  |  |  |
|-----------------------------|--|--|--|--|
| Session # 4                 | Specification   Kyle B Riding PhD, MLS(ASCP) <sup>CM</sup>   |  |  |  |
|                             | Speaker: Lecturer, University of Central Florida   |  |  |  |
|                             | The role of reticulated platelets in platelet disorders has been widely researched for a number of years. Advances in automation have allowed the clinical laboratory to provide this data in a more cost-efficient and timely manner. Understanding the impact of this parameter to clinical practice is critical to successful implementation.   |  |  |  |
|                             | <ul> <li>Level of Instruction: Intermediate (1.0 Contact Hour)</li> <li>Objectives: (Upon completion of the session, the participant will be able to)</li> <li>Recall the processes involved in megakarypoiesis and thrombopoiesis</li> <li>Explain the various methods involved in determining reticulated platelet concentrations</li> <li>Discuss the clinical significance of reticulated platelets</li> </ul>   |  |  |  |
|                             | Five Steps to Securing Your Retirement   |  |  |  |
| 4:30–5:30 PM<br>Session # 5 | Speaker: Erik Gaikowski State Director, AARP South Dakota  |  |  |  |
|                             | Session will include AARP's five steps to securing the retirement you want to live: defining what retirement means to you; taking inventory of your current portfolio; what are your current and future benefits; creating your budget; and how to stick to your plan  |  |  |  |
|                             | Level of Instruction: Basic (1.0 Contact Hour) Objectives: (Upon completion of the session, the participant will be able to)   |  |  |  |
|                             | Hemostasis and Women's Health:   |  |  |  |
| 4:30–5:30 PM<br>Session # 6 | The Laboratory's Role in Diagnosing Complex Disorders  |  |  |  |
|                             | Speaker: Tatsiana Mardovina MD, PhD Scientific Market Development, Stago   |  |  |  |
|                             | Women have specific health needs due to acquired hypercoagulable states which occur during different phases of life. For example, women may be at risk of thrombosis during pregnancy and the postpartum period due to certain underlying genetic and acquired disease states. This presentation will provide an overview of potential thrombotic and bleeding disorders and how management and treatment are provided, with special focus paid to antiphospholipid syndrome and disseminated intravascular coagulation  |  |  |  |
|                             | <ul> <li>Level of Instruction: Intermediate (1.0 Contact Hour)</li> <li>Objectives: (Upon completion of the session, the participant will be able to)</li> <li>Provide an overview of different disease states affecting women's health, including venous thromboembolism, antiphospholipid syndrome, pregnancy related thrombocytopenia and disseminated intravascular coagulation</li> <li>Discuss clinical guidelines establishing best practices for laboratory diagnosis of these disorders</li> <li>Identify the role of the lupus anticoagulant relative to pathological thrombosis in clinical situations</li> </ul> |  |  |  |
| 5:30-8:30 PM                | EXHIBITOR SOCIAL - EXHIBITS, FOOD, FUN & NETWORKING!   |  |  |  |

|                               | Friday, October 6, 2017  |  |  |  |
|-------------------------------|--|--|--|--|
| 7:30-8:00 AM                  | Registration & Buffet Breakfast  |  |  |  |
|                               |  |  |  |  |
| 8:15–9:15 AM<br>Session # K-2 | Morning Keynote<br>Diversity, Health Disparities and Social Determinants of Health:<br>Have We Moved the Needle?   |  |  |  |
|                               | Speaker: Chamika Hawkins-Taylor, MHA, PhD Assistant Professor, South Dakota State University   |  |  |  |
|                               | The United States demographics are ever changing. Compared to fifty years ago, the increasing diversity has been met with grave disparities in health that are determined by innumerable social determinants of health. This session compares the state of social determinants of health then and now, acknowledging progress and shortfalls.  |  |  |  |
|                               | <ul> <li>Level of Instruction: Intermediate (1.0 Contact Hour)</li> <li>Objectives: (Upon completion of the session, the participant will be able to)         <ul> <li>Discuss social determinants and disparities from a historical perspective</li> <li>Identify progress and shortfalls in improving social determinants of health</li> <li>Describe and appreciate the role of social determinants in influencing the health status of all citizens</li> <li>Identify and participate in discussions about policies and legislation to address disparities in health care that hve been impacted by social determinants</li> </ul> </li> </ul> |  |  |  |
|                               | Identification of Hard-Bodied Ticks  |  |  |  |
| 9:30–10:30 AM<br>Session # 7  | Speaker: Marijo Roiko PhD, D(ABMM) Microbiology Director, Altru Health System  |  |  |  |
|                               | Identification of ticks can provide clinically useful information regarding potential exposure to tick-borne pathogens. This presentation will focus on basic morphological features useful for identification of medically significant hard-bodied ticks found in the U.S. We will also discuss the tick life cycle and tick-borne pathogens.   |  |  |  |
|                               | Level of Instruction: Basic (1.0 Contact Hour)  Objectives: (Upon completion of the session, the participant will be able to)  Name four genera of medically significant hard-bodied ticks found in the U.S.  Describe a distinguishing morphological feature for each genus  Identify a tick-borne pathogen for each vector   |  |  |  |
| 9:30–10:30 AM<br>Session # 8  | Speaker:  Donna J. Spannaus-Martin PhD, MLS(ASCP) <sup>CM</sup> Professor, Faculty Legislative Liaison, University of Minnesota  |  |  |  |
|                               | Communicating with your legislators about healthcare issues has never seemed as important as it is today. In this session, you will learn the most effective ways to communicate with your legislators and the general public about healthcare and medical laboratory issues at both a state and national level.   |  |  |  |
|                               | Level of Instruction: Basic (1.0 Contact Hour)  Objectives: (Upon completion of the session, the participant will be able to)  • Define advocacy  • Describe the components of effective legislative advocacy  • Discuss the importance of professional organizations in advocacy  |  |  |  |
|                               |  |  |  |  |

| 10:45-11:45 AM                 | Cardiac Troponin: ER Utilization and the Next Generation   |                                  |  |  |  |
|--------------------------------|--|----------------------------------|--|--|--|
| Session # 9                    | Speaker:  Joshua Soldo BS  Modical & Scientific Affaire Cardiac Poche Diagnostics Corporation  |                                  |  |  |  |
|                                | Medical & Scientific Affairs Cardiac, Roche Diagnostics Corporation  |                                  |  |  |  |
|                                | Cardiac troponin (T and I) assays are used to aid in the diagnosis of myocardial infarction (MI). In a clinical setting consistent with MI, detection of a rise and/or fall of cTnT with at least one value above the 99 <sup>th</sup> percentile is the cornerstone of MI diagnosis. This session will teach how highly sensitive cardiac troponin assays are being used to identify patients who are safe for early discharge.   |                                  |  |  |  |
|                                | Level of Instruction: Intermediate (1.0 Contact Hour)  |                                  |  |  |  |
|                                | <ul> <li>Objectives: (Upon completion of the session, the participant will be able to)</li> <li>Explain the 3rd Universal Definition of MI and ACS guidelines</li> <li>Discuss the importance of serial testing and utilization of troponin at the series of the criteria for highly sensitive troponin assays to aid in the diagnose.</li> <li>Describe how highly sensitive troponin can help rule out MI</li> </ul>   |                                  |  |  |  |
|                                | Culture Shock: Stories and Demands Get You Nowhere   |                                  |  |  |  |
| 10:45-11:45 AM<br>Session # 10 | Speaker:  Brendon Sato MBA, MLS(ASCP) <sup>CM</sup> Laboratory Manager, Regional Health-Rapid City   |                                  |  |  |  |
|                                | By creating stories and making demands, staff create their own drama and expect<br>solve it for them. By shifting the focus from stories to facts and with a little self-<br>new culture of accountability (and fewer drams) can be created  |                                  |  |  |  |
|                                | Level of Instruction: Intermediate (1.0 Contact Hour)  Objectives: (Upon completion of the session, the participant will be able to)  Describe culture in the workplace  Recognize how workplace culture is influenced  Discuss simple tactics that can change workplace culture   |                                  |  |  |  |
| 40.00 4.45 500                 | Luncheon & Keynote: The Vampire Diaries:   |                                  |  |  |  |
| 12:00–1:15 PM<br>Session # K-3 | The Tale of Healthcare Acquired Anemia   |                                  |  |  |  |
|                                | Speaker: Kyle B Riding PhD, MLS(ASCP) <sup>CM</sup> Lecturer, University of Central Florida  |                                  |  |  |  |
|                                | The role of laboratory professionals in patient safety is ever-evolving and frequentl appreciated. While many opportunities exist for us to improve patient care, the link healthcare acquired anemia and laboratory utilization demonstrates the need for us become more involved in right-sizing utilization to limit the incidence of this iatroge and its associated adverse outcomes. This presentation will discuss this threat to and how our unique knowledge and skill set can assist and improve outcomes. | k between<br>s to<br>nic disease |  |  |  |
|                                | Level of Instruction: Intermediate (1.0 Contact Hour)  Objectives: (Upon completion of the session, the participant will be able to)   |                                  |  |  |  |
|                                | <ul> <li>State the causes, risk factors, and adverse outcomes associated with he<br/>acquired anemia</li> </ul>  | aitncare                         |  |  |  |
|                                | <ul> <li>Explain the relationship between laboratory misutilization and healthcare anemia</li> </ul>   |                                  |  |  |  |
|                                | <ul> <li>Describe the importance of laboratory professionals in improving patient<br/>limiting healthcare acquired anemia</li> </ul>   | safety and                       |  |  |  |
| 1:30-2:30 PM                   | Region V Council Meeting — Walnut Room   | ction                            |  |  |  |
|                                | all meeting attendees are welcome to experience ASCLS in a   | CUOII                            |  |  |  |

## A Special Thank You Goes Out To Our Supporting Industry Partners (Available at time of publication)

| Abbott Diagnostics           | ARUP Laboratories          | Avera McKennan                                      |
|------------------------------|----------------------------|---|
| Becton, Dickinson, & Co.     | BioFire Diagnostics        | Concordance Healthcare<br>Solutions (Kreisers, Inc) |
| Diasorin, Inc                | Instrumentation Laboratory | Mayo Medical Laboratories                           |
| Medical Chemical Corporation | MEDTOX Diagnostics, Inc    | Minnesota Medical Specialists                       |
| Roche Diagnostics            | Sanford Laboratories       | SCIEX   |
| Sysmex America               | United Blood Services      | WSLH Proficiency Testing                            |
|                              | ASCLS                      |   |
|                              |                            |   |
|                              |                            |   |
|                              |                            |   |
|                              |                            |   |
|                              |                            |   |